42 years, 700,000 visits, 260,000 endoscopies — a department that runs like a national service
To walk into the gastroenterology department of Renji Hospital in eastern Shanghai is to step into what is, by patient volume, the largest digestive-disease service in China. The department was founded in 1984 by Academician Jiang Shaoji and Professor Xiao Shudong, in parallel with the Shanghai Municipal Institute of Digestive Diseases, the first municipal-level digestive-disease research institute in the country. Four decades later, the department handles more than 700,000 outpatient visits a year — a number that has held the No.1 position in China for several years running — and performs more than 260,000 endoscopic procedures a year. It is the only place in China that publishes a full annual cycle of more than 200,000 endoscopies and a full annual visit count in seven figures, and is the only digestive-disease unit in the country whose own clinical protocols appear in international guidelines.
The department holds 166 inpatient beds across Renji's east, west, and south campuses, runs a 4,600-square-metre clinical endoscopy centre, and has 13 doctoral supervisors and 18 master's supervisors. The faculty includes 3 national high-level talents. In the 2024 Fudan Hospital Specialty Reputation Rankings, the Renji gastroenterology department was named China's leading digestive-disease unit for the fourth consecutive year.
What the place actually looks like
Where most digestive-disease units in the world are organised around a single organ or a single technology, the Renji department is organised around the full chain of digestive-disease care. The seven flagship subspecialty areas are: gastrointestinal cancer and its precancerous conditions; chronic liver disease (including autoimmune, drug-induced, fatty, and severe liver disease); H. pylori and its related diseases; inflammatory bowel disease; psychosomatic digestive disease; small-bowel bleeding; and endoscopic early-cancer diagnosis and treatment. The endoscopy centre alone has more than 30 procedure rooms and runs the country's largest H. pylori eradication programme.
That structural choice — a single department that handles every kind of digestive-disease problem in every kind of way, with the country's largest endoscopy platform attached — is the operational reason Renji has been able to keep the Fudan No.1 ranking for four consecutive years. A patient who walks in with what looks like a routine reflux problem can be scoped on the same campus by the same team the same week, with a referral to a hepatology or IBD subspecialist handled internally rather than across hospitals.
Why it became No.1
Three factors explain the Renji department's grip on the Fudan ranking. First, the Shanghai Municipal Institute of Digestive Diseases, which the department houses and which has been the country's primary research platform for H. pylori, autoimmune liver disease, and IBD since 1984 — four decades of accumulated clinical samples, animal models, and prospective cohorts that no other Chinese institution can match. Second, an unmatched research output: the department holds more than 200 National Natural Science Foundation of China grants and has published more than 500 SCI papers, with 4 National Science and Technology Progress Awards (as first completing unit) and approximately 30 ministerial-level science and technology awards. Third, and most distinctive internationally, the department is the originator of the standard 10-day bismuth-based quadruple therapy for H. pylori infection — the only Chinese H. pylori treatment regimen that has been adopted into international guidelines — and the originator of thalidomide for small-bowel vascular malformation bleeding, which the American College of Gastroenterology now strongly recommends in its international guideline.
That history matters for international patients because the Renji department does not just follow the international standard of care for H. pylori and IBD — it wrote parts of it.
What this means for international patients
For a foreign patient considering digestive-disease treatment in China, the Renji gastroenterology department is the place that handles the cases the rest of the country refers out. The department runs an international patient office and a multilingual case-coordination service across Renji's east, west, and south campuses. It is the host of the Shanghai Municipal Clinical Centre for Digestive Diseases and the Shanghai Quality Control Centre for Digestive Diseases, which means its clinical protocols are the de facto standard for digestive care in Shanghai and a reference for the rest of the Yangtze River Delta.
The department's specialty areas are anchored to internationally recognised strengths: H. pylori (where its quadruple therapy is the international standard of care in much of Asia), autoimmune liver disease (where its diagnostic criteria are quoted by international liver societies), IBD (where its centre is one of the largest in Asia), and endoscopic early-cancer diagnosis (where its procedure volume is the largest in China). The department is at 1630 Dongfang Road, Pudong New Area, Shanghai. This profile is editorial information based on the sources linked below, not treatment advice; individual outcomes depend on the disease, the stage, the team, and the patient.